Imcivree hypothalamic obesity data from the two-year extension of Rhythm Pharmaceuticals’ Phase 3 TRANSCEND trial, presented at ObesityWeek 2026 on 16 November, show patients on continuous setmelanotide kept an average 18.8% reduction in body mass index (BMI). Among the 81 patients who had completed two years, those who switched from placebo after the first year reached a 16.5% BMI cut, suggesting the drug’s effect is both durable and reproducible once treatment starts.
The readout lands as Rhythm sits at the centre of takeover interest: Reuters reported earlier this month that AstraZeneca had made a non-binding offer worth about $10 billion for the company.
Key takeaways on Imcivree for hypothalamic obesity
- Continuous setmelanotide: mean BMI down 18.8% at two years (adults 21.2%).
- Placebo-to-setmelanotide switchers: mean BMI down 16.5% at two years (adults 21.0%).
- Children’s BMI z-scores fell by 1.71 (continuous) and 1.49 (switchers).
- Year-two safety looked consistent with earlier studies: 52 of 125 patients had treatment-related side effects, none serious; one death was judged unrelated.
- Imcivree has been FDA-approved for acquired hypothalamic obesity in patients aged 4 and up since March 2026, and is also authorised in the EU and UK.
The two-year numbers
TRANSCEND randomised 142 patients aged 4 and older 2:1 to daily setmelanotide or placebo for 52 weeks. After the first year, 125 entered an open-label extension in which everyone received the drug. At the data cut, 81 had reached the two-year mark: 54 on setmelanotide throughout and 27 who started after a year on placebo.
| Measure | Continuous setmelanotide (n=54) | Placebo, then setmelanotide (n=27) |
|---|---|---|
| Mean BMI change, all ages | -18.8% | -16.5% |
| Mean BMI change, adults | -21.2% | -21.0% |
| BMI z-score change, children | -1.71 | -1.49 |
| Time on drug at analysis | About 2 years | About 1 year |
For context, the original 52-week analysis showed a 15.8% BMI fall on setmelanotide against a 2.6% rise on placebo, a placebo-adjusted gap of 18.4%. By our calculation, the continuous group therefore lost a further 3 percentage points of BMI in year two rather than plateauing or regaining, which is notable for a population that typically keeps gaining weight.
What acquired hypothalamic obesity is
The hypothalamus controls hunger and energy use. When it is damaged, most often by a brain tumour such as craniopharyngioma, by the surgery or radiation used to treat it, or by stroke or trauma, patients can develop relentless hunger and rapid weight gain that diet and exercise rarely control. Rhythm estimates about 10,000 people in the US live with the condition. A 17-member international panel also published a consensus definition at ObesityWeek, noting that the condition “can be difficult to recognize” and setting out diagnostic criteria built around a documented injury and a clear change in weight trajectory afterwards.
Why it is not just another weight-loss shot
Setmelanotide activates the melanocortin-4 receptor (MC4R), a step in the brain’s satiety pathway that sits downstream of the damaged hypothalamic signals. GLP-1 drugs such as semaglutide and tirzepatide act largely through gut hormone signalling and partly rely on intact hypothalamic circuits, which may explain why they tend to work less reliably in this group. That distinction is the commercial heart of Rhythm’s pitch: a targeted drug for a small, hard-to-treat population rather than a competitor in the mass obesity market. Readers can compare this with broader obesity results such as the real-world Wegovy pill data also presented at ObesityWeek.
Safety signals to keep in view
Imcivree’s label lists skin darkening, injection site reactions, nausea, headache, diarrhoea, abdominal pain, vomiting, depression and spontaneous erections among its most common reactions. Hypothalamic obesity patients carry extra risk because many have pituitary hormone deficits: in the label, acute adrenal insufficiency occurred in 5% of treated patients with secondary adrenal insufficiency versus none on placebo, and low sodium was seen in 6% versus 2% among those with central diabetes insipidus. The two-year release did not publish detailed event rates, which clinicians will want to see in full.
Market context and the AstraZeneca angle
Reuters reported on 4 November that AstraZeneca offered up to $134 a share, including milestones, through its Alexion rare-disease unit; the proposal was described as non-binding and neither company commented. Durable two-year data strengthen the case that Imcivree is a long-term therapy, which is what an acquirer would be paying for.
The broader category is growing quickly. Acumen Research and Consulting valued the global anti-obesity drugs market at USD 2.1 billion in 2022 and projects USD 8.2 billion by 2032, a 14.6% CAGR, with Asia-Pacific the fastest-growing region. Those figures predate the latest wave of GLP-1 launches and should be read as indicative, but they show why even niche obesity assets attract large bids.
Limits of the data
- The extension was open-label, with no placebo comparison in year two.
- Only 81 of 125 extension patients had reached two years; results for the other 44 are pending.
- Baseline values and full adverse event tables were not in the release.
FAQ
Is Imcivree approved for hypothalamic obesity?
Yes. The FDA approved it in March 2026 for adults and children aged 4 and older with acquired hypothalamic obesity, and it is authorised in the EU and UK for the same group.
How much weight do patients lose on setmelanotide?
In TRANSCEND, BMI fell an average 18.8% after two years of continuous treatment, and about 21% in adults.
How is Imcivree taken?
It is a once-daily injection under the skin, with the dose adjusted by age, weight and tolerability under medical supervision.
Is AstraZeneca buying Rhythm Pharmaceuticals?
Not confirmed. Reuters reported a non-binding offer of about $10 billion; no deal has been announced.
Sources: Rhythm Pharmaceuticals ObesityWeek 2026 release (16 November 2026); Reuters (4 and 16 November 2026). Market data: Acumen Research and Consulting, Anti-Obesity Drugs Market report (2023, indicative). More in Clinical Trials. Not medical or investment advice. Last updated 17 November 2026.
